Quantcast
Last updated on April 19, 2014 at 17:21 EDT

Latest MAP Pharmaceuticals Inc. Stories

2013-01-30 12:27:10

NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Morgan & Morgan is investigating the Board of Directors of MAP Pharmaceuticals Inc. ("MAP" or the "Company") (Nasdaq: MAPP) for possible breaches of fiduciary duty and other violations of law related to the sale of the Company to Allergan Inc. If you are a current shareholder of MAP and are interested in learning more about our MAP Pharmaceuticals merger investigation, please contact George Pressly, Esq. at 1 (800) 631-6234 or email George at...

2013-01-24 12:27:13

WAYNE, Pa., Jan. 24, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/mapp) is investigating potential claims against the board of directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ: MAPP) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Allergan, Inc. in a transaction valued at approximately $958 million. (Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO...

2013-01-24 12:27:10

NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ: MAPP) concerning the proposed acquisition of the Company by Allergan, Inc. ("Allergan") in a transaction valued at approximately $958 million. (Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO ) On January 24, 2013, MAP announced that it had entered into a definitive...

2013-01-24 08:32:04

NEW YORK, January 24, 2013 /PRNewswire/ -- Fourth-quarter revenues reported by tech giants IBM and AMD gave the markets a boost yesterday. IBM rallied more than 4% to hit $204.72 as their profit forecast beat analyst estimates. AMD, the second-biggest maker of processors for personal computers, also beat analyst estimates and rose more than 10% to hit $2.73. Apple reported weaker than expected first-quarter sales, dragging the stock down more than 10% after hours. Whether...

2013-01-23 16:24:24

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of MAP Pharmaceuticals, Inc. ("MAP Pharmaceuticals" or the "Company") (NASDAQ: MAPP) (ISIN: US56509R1086) (CUSIP: 56509R108) concerning the proposed acquisition of MAP Pharmaceuticals by Allergan, Inc. in a transaction valued at approximately $985 million in cash. The investigation concerns whether the MAP Pharmaceuticals directors are breaching their...

2013-01-23 08:25:18

BOSTON, Jan. 23, 2013 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ: MAPP) concerning the proposed acquisition of the Company by Allergan, Inc. ("Allergan") in an all cash tender offer expected to close late in the first quarter or in the second quarter of 2013....

2013-01-02 16:22:53

MOUNTAIN VIEW, Calif., Jan. 2, 2013 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 3:30 p.m. PT in San Francisco. A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following the presentation....

2012-11-21 16:22:12

MOUNTAIN VIEW, Calif., Nov. 21, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) resubmission for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has classified the resubmission as a complete, Class 2 response to the FDA's March 26, 2012 action letter and has set a goal date of April 15, 2013...

2012-11-08 16:29:01

MOUNTAIN VIEW, Calif., Nov. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Lazard Capital Markets 9(th) Annual Healthcare ConferenceTuesday, November 13, at 11:00 a.m. ET in New York Credit Suisse 2012 Healthcare ConferenceWednesday, November 14, at 3:30 p.m. MT in Phoenix A live webcast of each presentation will be available on the Investor Relations section of MAP Pharmaceuticals'...

2012-11-01 15:28:45

MOUNTAIN VIEW, Calif., Nov. 1, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2012. The net loss for the three months ended September 30, 2012 was $12.6 million, compared to net income of $8.2 million during the same period in 2011. The net loss for the nine months ended September 30, 2012 was $43.8 million, compared to a net loss of $19.1 million during the same period in 2011. The...